InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression (TREASURE)

This open-label Phase III trial (n=31) will assess the feasibility and efficacy of combining intravenous ketamine (35mg/70kg over 45 minutes) with immersive virtual reality (VR) for the treatment of adults with treatment-resistant depression (TRD).

Conducted by Sunnybrook Health Sciences Centre, the TREASURE trial aims to determine whether VR can enhance the therapeutic effects of ketamine.

In Phase I, a small group (n=3-5) will help refine the VR experience. In Phase II, participants (n=26) will be randomly assigned to receive either standard ketamine treatment alone or ketamine combined with a VR headset displaying calming outdoor scenes. Each participant will receive four ketamine infusions (twice per week for two weeks), with follow-ups assessing mood, anxiety, dissociative effects, cognitive function, and neural activity. The study seeks to inform the development of a larger trial to evaluate the combined treatment’s effectiveness.

Topic Treatment-Resistant Depression Depression
Compound Ketamine
Country Canada
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Sunnybrook Health Sciences Centre
This company doesn't have a full profile yet, it is linked to a clinical trial.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.